We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+3.08%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$429M
AUM Growth
-$47.2M
Cap. Flow
-$18.8M
Cap. Flow %
-4.39%
Top 10 Hldgs %
52.29%
Holding
44
New
14
Increased
9
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
BCAB icon
BioAtla
BCAB
+$32.9M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$22.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$16.6M
4
RFL icon
Rafael Holdings
RFL
+$13.3M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$12.2M

Top Sells

Rank Stock Value
1
PODD icon
Insulet
PODD
+$28.7M
2
UTHR icon
United Therapeutics
UTHR
+$17.7M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$16.2M
4
COLL icon
Collegium Pharmaceutical
COLL
+$16M
5
FOLD
Amicus Therapeutics
FOLD
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Real Estate 2.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.3B
$32.2M 7.51%
1,525,000
+130,893
+9% +$2.43M
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
$31.6M 7.36%
530,670
+25,000
+5% +$1.48M
KDMN
3
DELISTED
Kadmon Holdings, Inc.
KDMN
$29.4M 6.84%
3,375,000
-1,455,000
-30% -$8.29M
BCAB icon
4
BioAtla
BCAB
$5.46M
$24.8M 5.79%
+16,880
New +$32.9M
RCKT icon
5
Rocket Pharmaceuticals
RCKT
$340M
$22.9M 5.32%
765,000
-52,040
-6% -$1.89M
MGNX icon
6
MacroGenics
MGNX
$235M
$20.9M 4.88%
1,000,000
-378,495
-27% -$9.12M
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$16.1M 3.76%
+799,999
New +$22.1M
UTHR icon
8
United Therapeutics
UTHR
$25.8B
$16M 3.72%
86,667
-89,739
-51% -$17.7M
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$121B
$15.4M 3.59%
+85,000
New +$16.6M
TVTX icon
10
Travere Therapeutics
TVTX
$5.2B
$15.2M 3.53%
625,000
-459,300
-42% -$8.44M
ANAB icon
11
AnaptysBio
ANAB
$1.58B
$14.9M 3.47%
549,545
+149,494
+37% +$3.79M
CYTK icon
12
Cytokinetics
CYTK
$10.5B
$14M 3.26%
+391,429
New +$11.5M
BIIB icon
13
Biogen
BIIB
$30B
$13.4M 3.13%
47,500
+15,000
+46% +$4.92M
URGN icon
14
UroGen Pharma
URGN
$1.86B
$12.6M 2.94%
+750,000
New +$11.9M
DYN icon
15
Dyne Therapeutics
DYN
$4.7B
$12.1M 2.82%
745,000
+72,441
+11% +$1.28M
SAGE
16
DELISTED
Sage Therapeutics
SAGE
$11.9M 2.78%
269,010
+19,010
+8% +$872K
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.06B
$10.7M 2.49%
+700,000
New +$12.2M
TCDA
18
DELISTED
Tricida, Inc. Common Stock
TCDA
$9.16M 2.13%
1,974,000
– –
PBYI icon
19
Puma Biotechnology
PBYI
$404M
$9.11M 2.12%
1,300,000
– –
OLMA icon
20
Olema Pharmaceuticals
OLMA
$1B
$9.07M 2.11%
329,086
– –
NKTR icon
21
Nektar Therapeutics
NKTR
$2.39B
$9.06M 2.11%
+33,646
New +$8.09M
ACRS icon
22
Aclaris Therapeutics
ACRS
$726M
$9M 2.1%
+500,000
New +$8.02M
RFL icon
23
Rafael Holdings
RFL
$101M
$8.78M 2.04%
+289,714
New +$13.3M
DNTH icon
24
Dianthus Therapeutics
DNTH
$5.84B
$8.52M 1.98%
73,125
+3,681
+5% +$429K
CTMX icon
25
CytomX Therapeutics
CTMX
$675M
$7.63M 1.78%
1,500,000
+500,000
+50% +$2.68M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Great Point Partners held 44 positions worth $429M, down 9.9% from $477M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners withdrew a net $18.8M in Q3 2021, closing 8 positions and reducing 9 holdings. Its most notable exit was Insulet, an estimated $28.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Real Estate.

Against the trend, Great Point Partners opened a new position in BioAtla worth $24.8M.

  • Great Point Partners's largest Q3 2021 buy was BioAtla: 16,880 shares worth $24.8M.
  • Great Point Partners added most to Biogen in Q3 2021, an estimated $4.92M increase.
  • Great Point Partners's biggest Q3 2021 reduction was United Therapeutics, cutting an estimated $17.7M.
  • Great Point Partners fully exited Insulet in Q3 2021, selling an estimated $28.7M.
  • Great Point Partners's ten largest holdings make up 52% of its $429M portfolio in Q3 2021.
  • Great Point Partners opened 14 new positions and closed 8 in Q3 2021.
  • Great Point Partners's portfolio value fell 9.9% quarter-over-quarter to $429M.

Based on Great Point Partners's 13F filing for Q3 2021, filed 15 Nov 2021.